Fosinopril
Based on 3 publication(s) in Google Scholar
Fosinopril (SQ28555 free acid) is the ester proagent of angiotensin-converting enzyme (ACE) inhibitor with an IC50 value of 0.18 μM. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with an Ki value of 1.675 μM.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 98048-97-6
- 分子式: C30H46NO7P
- 分子量:563.66
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Fosinopril
More
生物活性
Fosinopril (0-100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2[1].
Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2[1].
Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with an Ki value of 1.675 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Fosinopril (4.67 mg/kg; p.o.; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g) [3]
-
Dosage:4.67 mg/kg
-
Administration:Oral gavage; 4 weeks
-
Result:Inhibited cardiac dysfunction and structural alteration and suppressed apoptosis.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 98048-97-6
-
分子量 563.66
-
分子式 C30H46NO7P
-
SMILES
O=C(O)[C@H]1N(C(C[P@@](CCCCC2=CC=CC=C2)(O[C@H](OC(CC)=O)C(C)C)=O)=O)C[C@H](C3CCCCC3)C1
-
別名
SQ28555 free acid
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
ACS Appl Mater Interfaces
Insights into the Mechanism of Supramolecular Self-Assembly in the Astragalus membranaceus- Angelica sinensis Codecoction. [Abstract]2023 Oct 18;15(41):47939-47954. PMID: 37791782 -
-
純度とドキュメンテーション
参考文献
[1]. Ondetti, M.A., Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation, 1988. 77(6 Pt 2): p. I74-8. [Content Brief]
[2]. Piepho, R.W., Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm, 2000. 57 Suppl 1: p. S3-7. [Content Brief]
[3]. Sharma, S., et al., The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther, 1999. 6(4): p. 181-9. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Fosinopril 関連分類
HY-B0690 関連分類
Powered by Bioz